Impact of Aspirin Supplementation for Pre-Eclampsia Prevention on Neonatal Outcomes

Authors

  • Bertha Campo, M.D. Nassau University Medical Center
  • Joshua Fogel, Ph.D. Brooklyn College
  • Sean Na, B.A. Stony Brook University
  • Lennox Bryson, M.D. Nassau University Medical Center

DOI:

https://doi.org/10.17161/kjm.vol16.18138

Keywords:

Aspirin, Birth weight, Hispanics, Pre-Eclampsia, Neonatal Intensive Care

Abstract

Introduction. Preeclampsia affects approximately 4.6% of pregnancies worldwide. In 2018, ACOG updated their low dose aspirin (LDA) supplementation recommendation to include pregnant women at moderate risk for preeclampsia. In addition to the potential benefit of LDA supplementation for delaying or preventing preeclampsia, LDA supplementation can affect neonatal outcomes. We study the association of LDA supplementation with six neonatal outcomes: length of stay (LOS) in hospital, NICU admission, hospital readmission, birth weight (BW), one-minute Apgar score, and five-minute Apgar score in a sample of mostly minority pregnant women from Hispanic and Black race/ethnicities.

Methods. This was a retrospective study of 634 patients from January 2018 through April 2021.Our main predictor variable was maternal LDA supplementation on 6 neonatal outcomes: NICU admission, neonatal readmission, one and five minute Apgar scores, neonatal BW and hospital LOS. We adjusted for demographics, comorbidities and maternal high- or moderate-risk designation per ACOG guidelines.

Results. We found that high-risk designation was associated with neonatal increased rate of NICU admission (OR: 3.80, 95% CI: 2.02, 7.13, p<0.001), LOS (B=0.15, SE=0.04, p<0.001) and decreased birthweight (B=-442.10, SE=75.07, p <0.001). We found no significant association with LDA supplementation and NICU admission, readmission, low one and five minute Apgar scores, BW and LOS.

Conclusions. We did not find any association of LDA supplementation with NICU admission, hospital readmission, low one-minute or five-minute Apgar score, birthweight, and LOS. Clinicians recommending maternal LDA supplementation should be aware that LDA supplementation does not appear to provide any benefits for these neonatal outcomes.

Metrics

Metrics Loading ...

Author Biographies

  • Bertha Campo, M.D., Nassau University Medical Center

    Obstetrics and Gynecology

    Resident Physician

  • Joshua Fogel, Ph.D., Brooklyn College

    Department of Business Management

    Faculty

  • Sean Na, B.A., Stony Brook University

    Renaissance School of Medicine

    Student

  • Lennox Bryson, M.D., Nassau University Medical Center

    Obstetrics and Gynecology

    Faculty

Downloads

Published

2023-02-21

Issue

Section

Original Research

How to Cite

Campo, B., Fogel, J., Na, S., & Bryson, L. (2023). Impact of Aspirin Supplementation for Pre-Eclampsia Prevention on Neonatal Outcomes. Kansas Journal of Medicine, 16(1), 41-47. https://doi.org/10.17161/kjm.vol16.18138